Literature DB >> 15851142

Diagnostic information in implantable devices that pertain to endpoints in atrial fibrillation studies.

Rahul Mehra1, Paul Ziegler, Jodi Koehler.   

Abstract

Implantable devices can store significant information about physiologic parameters relating to rhythm and rate control. The primary objective of our analysis was to evaluate the relationship between changes in these parameters and changes in clinical outcomes in patients with atrial tachyarrhythmias (AT). Because the present guidelines do not provide quantitative definition of rhythm and rate control, we used the percent of time in AT and frequency of such episodes as measures of rhythm control. Rate control was measured as the percent of time spent at a ventricular rate >120 beats/min, as well as the median ventricular rate during AT. Analysis was conducted in 643 patients with a history of AT and bradycardia receiving pacemakers to evaluate whether changes in these parameters were correlated with changes in cardiac hospitalization rates and SF-36 and symptom checklist scores. All patients were followed at 1, 4, and 7 months postimplant, during which rhythm and rate control data were collected. Positive correlation was observed between changes in cardiac hospitalization rate and changes in AT burden, as well as frequency of AT (P = 0.01, r = 0.08 for each). Changes in SF-36 or symptom checklist scores did not correlate with changes in rhythm and rate control measures. This patient cohort had relatively asymptomatic atrial fibrillation (symptom checklist frequency and severity scores of 14.3 +/- 9.5 and 11.5 +/- 7.9, respectively), and this may have contributed to the lack of correlation with SF-36 and symptom scores. Data stored in implantable devices offer a unique opportunity to monitor parameters of rhythm as well as rate control in patients with AT. In patients implanted with pacemakers for management of bradyarrhythmias who have a history of AT, a significantly positive but weak correlation was observed between changes in rhythm control measures (AT burden and frequency) and changes in cardiac hospitalization rate.

Entities:  

Mesh:

Year:  2004        PMID: 15851142     DOI: 10.1016/j.hrthm.2004.04.010

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  2 in total

1.  The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study.

Authors:  Dionyssios Leftheriotis; Panayota Flevari; George Theodorakis; Angelos Rigopoulos; Ignatios Ikonomidis; Fotis Panou; Vassilios Sourides; Panagiotis Simitsis; Georgios Giannakakis; Isaac Aidonidis; Ioannis Rizos; Maria Anastasiou-Nana
Journal:  J Atr Fibrillation       Date:  2014-02-28

2.  A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.

Authors:  Michael D Ezekowitz; Kenneth A Ellenbogen; John P DiMarco; Karoly Kaszala; Alexander Boddy; Gregory P Geba; Gregory Geba P; Andrew Koren
Journal:  J Interv Card Electrophysiol       Date:  2015-02-01       Impact factor: 1.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.